C2N Diagnostics’ Post

"Our study identified significantly elevated Glutamate and N-acetyl-aspartate levels in long COVID and ME/CFS patients compared with healthy controls. No significant differences in brain neurochemicals were observed between the two patient cohorts, suggesting a potential overlap in their underlying pathology. These findings suggest that imbalanced neurochemicals contribute to the complex symptoms experienced by #longCOVID and #MECFS patients." #pwme #myalgicE #millionsmissing https://lnkd.in/eY-EAbpj

Excited to share that a paper stemming from my PhD project, titled "BDNF sensitizes bone and joint afferent neurons at different stages of MIA-induced osteoarthritis", has been published in Bone Journal. This work was supported by funding from the Australian National Health and Medical Research Council (NHMRC) and the University of Melbourne School of Biomedical Sciences Early and Mid-Career Association Collaborative Research Award. Our research sheds light on the critical role of BDNF/TrkB signaling in osteoarthritis (OA) pain. By demonstrating that TrkB is expressed in neurons innervating the knee joint and bone, and that BDNF application enhances their mechanical sensitivity, we provide valuable insights into the mechanisms underlying OA pain. Additionally, our findings reveal how BDNF expression changes throughout the disease progression, suggesting a potential therapeutic window for intervention. Importantly, TrkB inhibition effectively reverses sensitivity alterations at different stages of OA, indicating that targeting this pathway could offer new strategies for managing OA pain and improving patients' lives. I’d like to thank everyone who contributed to this work. Your insights were invaluable! Looking forward to your thoughts and discussions! #Osteoarthritis #Pain #Nociceptive_pain #Nociceptors #Sensory_neurons #BDNF #TrkB #Joint #Bone #Research #Publication #Neuroscience #Neuroinflammation https://lnkd.in/gq-REACb

Here's the first in vivo evidence of increased TSPO expression and inflammation within the brains of patients with growing sporadic vestibular schwannomas. This work from the team at Manchester Centre for Clinical Neurosciences (part of Northern Care Alliance NHS Foundation Trust), Geoffrey Jefferson Brain Research Centre & The University of Manchester Faculty of Biology, Medicine and Health provides a potential mechanistic insight into the development of non-auditory symptoms in these patients and highlight the need for further studies interrogating the role of neuroinflammation in driving VS symptomatology. https://lnkd.in/eivEHS_7

Exciting news from the Focused Ultrasound Foundation as they highlight RebrAIn and its outstanding Medical Advisory Board in a recent article! The future of precision targeting for neurological conditions looks more promising than ever. #ArtificialIntelligence #AI #MachineLearning #SaMD #MovementDisorders #MedicalAdvisoryBoard

Amyloid and Tau models recapitulate pathological processes found in patients with Alzheimer’s Disease, including protein aggregation, neuroinflammation, neurodegeneration, and cognitive impairments. The key to understanding a therapeutic compound’s effect on amyloid-beta pathology-induced neuroinflammation, is to use robust and reliable models that consistently show progressive plaque pathology, such as the APP/PS1 (ARTE10) model. View example histopathological data here: https://lnkd.in/eKhpC6nX To view other models, browse through InnoSer's portfolio here: https://lnkd.in/ejQFTpA6 👉 Do you have specific questions relating to our Alzheimer's disease models? Our InnoSer neurology team is exhibiting (booth #22) at the upcoming #ADPD2024 conference and will be happy to answer any of your questions relating to Alzheimer's or other neurodegenerative disease models.

Are you ready for a new leading biomarker of nerve cell damage? The Neurofilament Light Chain assay for multiple sclerosis, developed by Siemens Healthineers is the first of its kind to achieve CE Mark. Siemens Healthineers plans to launch the NfL assay in Europe later this year. What is NfL?: Neurofilament light chain (NfL) is a protein released into the bloodstream upon nerve cell damage. In MS, the immune system mistakenly attacks the myelin sheath, causing damage to nerve fibers and regions called lesions. As nerve cells are progressively damaged, they release NfL into the cerebrospinal fluid, which then reaches circulation after crossing the blood-brain barrier The NfL assay is Siemens Healthineers’ global entry into Neurology with the first CE-marked NfL blood test for Multiple Sclerosis. NfL may aid in identifying MS-related neuronal injury earlier to support better management of the disease. The test will be useful alongside other clinical, imaging, and laboratory findings to help predict the risk of MS disease activity in a patient with Relapsing Multiple Sclerosis (RMS).  Siemens Healthineers is well-positioned to support neurological diseases with tests that can be run on widely accessible laboratory platforms, making these types of tests available to more physicians for their patients. Link below for full story⬇  https://lnkd.in/dEinqseg #neurology #siemenshealthineers #atellica  #nfl #multiplesclerosis

Latest from our team and colleagues at Northern Care Alliance NHS Foundation Trust, The University of Manchester Faculty of Biology, Medicine and Health and Manchester Centre for Clinical Neurosciences: Evidence for inflammation in normal appearing brain regions in patients with growing sporadic vestibular schwannoma: a PET study. Non-auditory symptoms can be a prominent feature in patients with sporadic vestibular schwannoma (VS), but the cause of these symptoms is unknown. Within this study, we demonstrate for the first time in vivo, using a dedicated PET tracer, that in patients with growing sporadic VS, there is widespread translocator protein (TSPO) upregulation within normal-appearing brain regions, indicative of microglial activation. We further demonstrate through a voxel-wise cluster analysis that this TSPO upregulation occurs within the non-auditory motor and premotor frontal lobe regions. This work provides an important possible pathophysiological explanation for the non-audio vestibular and neuropsychological symptoms experienced by patients with sporadic VS and a potential future therapeutic target (i.e. reversible inflammation) for these symptoms. These results highlight the need for further studies interrogating the role of neuroinflammation in patients with VS and other extra-axial CNS tumours.

I am happy to share our new work "Quantifying Carotid Stenosis: History, Current Applications, Limitations, and Potential: How Imaging Is Changing the Scenario" For years, the degree of carotid artery stenosis has been the North Star guiding therapeutic strategies for patients with carotid atherosclerosis. This seemingly simple biomarker has been a cornerstone in decision-making processes. However, as this paper intricately unravels, its application and models are anything but straightforward. This work was also contributed by Allan Fox the lead neuroradiologist from the NASCET study and offers a re-evaluation of a familiar yet complex biomarker in carotid atherosclerosis. https://lnkd.in/dPSQjBQr #Neurology #Radiology #VascularMedicine #ArtificialIntelligence #HealthcareInnovation

Join our upcoming webinar on Patient Centricity in Neurodegenerative Diseases on July 11th and learn how to integrate patient-centric approaches in clinical research. Neurodegenerative diseases have a profound impact on patients, caregivers, and healthcare systems. While advancements have been made, there's a critical need to amplify patient and caregiver voices throughout the research journey. This webinar brings experienced voices across the pharma industry and patient organizations to discuss: • Current advances in patient-centric precision medicine in action • The crucial role of biomarkers in treatment development • Why patient & caregiver input matters in clinical trial design and execution Register now and ensure patients are at the forefront of research! https://lnkd.in/ehUt-mD7 Moderator: Vikas Mohan Sharma, Global Head of Neuroscience and Ophthalmology, Fortrea  #CNS #NeurodegenerativeDisorders #PatientCentricity #DigitalBiomarkers #ImagingBiomarkers #ClinicalTrialEndpoints #COA #Parkinsons #Alzheimers #ClinicalTrials #PrecisionMedicine

At Vedarx, Vedagenetics is transforming the future of healthcare with our advanced Next-Generation Sequencing (NGS) solutions, designed to enhance diagnostics and treatment in Cardiology and Neurology. Our cutting-edge genetic testing services offer precise diagnosis, risk assessment, and tailored treatment plans, enabling healthcare professionals to provide exceptional care. In Cardiology, our NGS panels pinpoint genetic variants linked to inherited cardiac conditions like hypertrophic cardiomyopathy and arrhythmias. This invaluable data empowers clinicians to craft targeted therapies and preventive strategies, leading to improved patient outcomes. In Neurology, our NGS services address complex neurological disorders, from epilepsy and intellectual disabilities to neurodegenerative diseases such as Alzheimer's and Parkinson's. By uncovering genetic underpinnings, we enable healthcare providers to personalize treatments, enhancing care quality and patient well-being. Discover how Vedagenetics is redefining patient care by visiting www.vedarx.in. Explore our innovative Cardiology and Neurology NGS services at Vedarx and see how we can support your patients' journey toward better health. #Healthcare #Genomics #NGS #Cardiology #Neurology #PersonalizedMedicine #Vedagenetics